No spam. Unsubscribe anytime.
Triple Incretin Comparator Kit
Single, dual, and triple agonists — the three compounds studied in STEP, SURPASS, and NEJM Phase 2 trials
All three incretin agonist classes from published clinical trials in one kit. Semaglutide anchors with pure GLP-1 data (STEP trials), Tirzepatide adds dual GIP/GLP-1 findings (SURPASS trials), and Retatrutide provides the newest triple-agonist data covering GLP-1/GIP/glucagon receptor activation (NEJM Phase 2). Enables side-by-side study of single, dual, and triple-receptor mechanisms as described in peer-reviewed literature.
$42.89/vial avg · 12 vials total · Everything you need
What Studies Show
Observations reported in published research on the compounds in the Triple Incretin Comparator Kit research kit
Published trial data across all three compounds reported early appetite modulation via distinct receptor pathways. Weeks 3-4: STEP and SURPASS data documented consistent metabolic changes in study cohorts. Weeks 6-8: Trial participants showed measurable body composition changes across all three mechanisms. Weeks 12+: Published endpoints from NEJM and Lancet trials demonstrated 15-22% metabolic outcomes over extended protocols.
What the Research Shows
Peer-reviewed findings on each compound and their complementary mechanisms
Semaglutide activates GLP-1 receptors to regulate appetite signaling — the same validated mechanism studied in Ozempic/Wegovy clinical trials (PMID: 33567185).
Tirzepatide engages both GLP-1 and GIP receptors simultaneously. Published SURPASS data shows this dual-agonist approach produces measurably different metabolic outcomes than GLP-1 alone (PMID: 35658024).
Retatrutide is a triple-agonist (GLP-1/GIP/glucagon). Phase 2 trial data published in NEJM showed its tri-receptor mechanism adds a direct lipolysis pathway not present in the other two compounds (PMID: 37351564).
This combination provides research flexibility to study single, dual, and triple-receptor activation independently or in sequence.
Research Dosing Reference
Dosing ranges cited in published studies — 12-20 weeks research protocol
Semaglutide
Tirzepatide
Retatrutide
Research Protocol Notes
Published protocols reference single-agent or dual-agent use. Sequencing studies typically initiate with Semaglutide for tolerance establishment, then transition to Tirzepatide or Retatrutide. All three require gradual dose escalation over 4-6 weeks per published titration schedules.
What's in This Kit
3 peptides, each with individual COA documentation
Retatrutide
$71.95Triple-receptor agonist studied for enhanced metabolic activity
Retatrutide is a research peptide in the glp-1 / weight management category. Retatrutide is a triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors. MiPeptidos offers Retatrutide in 6 sizes with 99.4% verified purity and full analytical documentation.
Tirzepatide
$41.95The most studied dual-agonist for weight reduction
Tirzepatide is a research peptide in the glp-1 / weight management category. Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. MiPeptidos offers Tirzepatide in 10 sizes with 99.2% verified purity and full analytical documentation.
Semaglutide
$46.95Clinically studied for steady weight reduction — once weekly
Semaglutide is a research peptide in the glp-1 / weight management category. Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release. MiPeptidos offers Semaglutide in 6 sizes with 99.1% verified purity and full analytical documentation.
What Customers Say
Reviews from customers using peptides in this research kit
Frequently Asked Questions
Common questions about the Triple Incretin Comparator Kit research kit
Related Research Kits
Incretin Pathway Comparator Kit
Single vs. dual receptor activation — the compounds from the STEP and SURPASS trials
2 peptides · Metabolic Research
Lipolytic Pathway Study Kit
Three lipolytic mechanisms studied in published research — HGH-fragment activity plus mitochondrial oxidation
3 peptides · Metabolic Research
Tissue Repair Research Kit
The two most-cited tissue repair peptides studied together in published literature
2 peptides · Tissue Research
Start Your Research
Get the complete Triple Incretin Comparator Kit at $136.72 — save $24.13 versus purchasing each compound separately. Full COA documentation included with every vial.
Research Use Only. These products are intended for laboratory research purposes only. Not for human consumption. Dosing information is provided for research reference only. Consult a licensed healthcare provider before beginning any peptide protocol.